These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36899051)

  • 1. Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling.
    Walter DM; Gladstein AC; Doerig KR; Natesan R; Baskaran SG; Gudiel AA; Adler KM; Acosta JO; Wallace DC; Asangani IA; Feldser DM
    Commun Biol; 2023 Mar; 6(1):255. PubMed ID: 36899051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic
    Walter DM; Venancio OS; Buza EL; Tobias JW; Deshpande C; Gudiel AA; Kim-Kiselak C; Cicchini M; Yates TJ; Feldser DM
    Cancer Res; 2017 Apr; 77(7):1719-1729. PubMed ID: 28202515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma.
    Zhou Y; Zheng X; Xu B; Deng H; Chen L; Jiang J
    Aging (Albany NY); 2020 Nov; 12(24):25189-25206. PubMed ID: 33223508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis.
    Xie Y; Sahin M; Wakamatsu T; Inoue-Yamauchi A; Zhao W; Han S; Nargund AM; Yang S; Lyu Y; Hsieh JJ; Leslie CS; Cheng EH
    JCI Insight; 2023 Feb; 8(4):. PubMed ID: 36810256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SETD2, an epigenetic tumor suppressor: a focused review on GI tumor.
    Hu M; Hu M; Zhang Q; Lai J; Liu X
    Front Biosci (Landmark Ed); 2020 Jan; 25(4):781-797. PubMed ID: 31585917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SETD2: an epigenetic modifier with tumor suppressor functionality.
    Li J; Duns G; Westers H; Sijmons R; van den Berg A; Kok K
    Oncotarget; 2016 Aug; 7(31):50719-50734. PubMed ID: 27191891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway.
    Zheng X; Luo Y; Xiong Y; Liu X; Zeng C; Lu X; Wang X; Cheng Y; Wang S; Lan H; Wang K; Weng Z; Bi W; Gan X; Jia X; Wang L; Wang Y
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methyltransferase SETD2 inhibits tumor growth and metastasis via STAT1-IL-8 signaling-mediated epithelial-mesenchymal transition in lung adenocarcinoma.
    Yang X; Chen R; Chen Y; Zhou Y; Wu C; Li Q; Wu J; Hu WW; Zhao WQ; Wei W; Shi JT; Ji M
    Cancer Sci; 2022 Apr; 113(4):1195-1207. PubMed ID: 35152527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis.
    Yuan H; Li N; Fu D; Ren J; Hui J; Peng J; Liu Y; Qiu T; Jiang M; Pan Q; Han Y; Wang X; Li Q; Qin J
    J Clin Invest; 2017 Sep; 127(9):3375-3391. PubMed ID: 28825595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis.
    Niu N; Lu P; Yang Y; He R; Zhang L; Shi J; Wu J; Yang M; Zhang ZG; Wang LW; Gao WQ; Habtezion A; Xiao GG; Sun Y; Li L; Xue J
    Gut; 2020 Apr; 69(4):715-726. PubMed ID: 31300513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma.
    Li J; Kluiver J; Osinga J; Westers H; van Werkhoven MB; Seelen MA; Sijmons RH; van den Berg A; Kok K
    Neoplasia; 2016 Jun; 18(6):339-46. PubMed ID: 27292023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
    Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
    Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.
    Xiang W; He J; Huang C; Chen L; Tao D; Wu X; Wang M; Luo G; Xiao X; Zeng F; Jiang G
    Oncotarget; 2015 Feb; 6(6):4066-79. PubMed ID: 25714014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deficiency of Histone Methyltransferase SET Domain-Containing 2 in Liver Leads to Abnormal Lipid Metabolism and HCC.
    Li XJ; Li QL; Ju LG; Zhao C; Zhao LS; Du JW; Wang Y; Zheng L; Song BL; Li LY; Li L; Wu M
    Hepatology; 2021 May; 73(5):1797-1815. PubMed ID: 33058300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C1orf74 positively regulates the EGFR/AKT/mTORC1 signaling in lung adenocarcinoma cells.
    Guo J; Li A; Guo R; He Q; Wu Y; Gou Y; Jin J; Huang G
    PeerJ; 2022; 10():e13908. PubMed ID: 36032960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.
    Duns G; van den Berg E; van Duivenbode I; Osinga J; Hollema H; Hofstra RM; Kok K
    Cancer Res; 2010 Jun; 70(11):4287-91. PubMed ID: 20501857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt/β-catenin signaling.
    Jiang C; He C; Wu Z; Li F; Xiao J
    Biochem Biophys Res Commun; 2018 Jul; 502(3):382-388. PubMed ID: 29842882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SETD2 epidermal deficiency promotes cutaneous wound healing via activation of AKT/mTOR Signalling.
    Li X; Liu C; Zhu Y; Rao H; Liu M; Gui L; Feng W; Tang H; Xu J; Gao WQ; Li L
    Cell Prolif; 2021 Jun; 54(6):e13045. PubMed ID: 33949020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
    Skoulidis F; Byers LA; Diao L; Papadimitrakopoulou VA; Tong P; Izzo J; Behrens C; Kadara H; Parra ER; Canales JR; Zhang J; Giri U; Gudikote J; Cortez MA; Yang C; Fan Y; Peyton M; Girard L; Coombes KR; Toniatti C; Heffernan TP; Choi M; Frampton GM; Miller V; Weinstein JN; Herbst RS; Wong KK; Zhang J; Sharma P; Mills GB; Hong WK; Minna JD; Allison JP; Futreal A; Wang J; Wistuba II; Heymach JV
    Cancer Discov; 2015 Aug; 5(8):860-77. PubMed ID: 26069186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
    Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.